# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug...
Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential ...
Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous...
Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavaila...
Planning well underway for Phase 2 of TH104 in primary biliary cholangitis (PBC) patients suffering from moderate-to-severe c...